Combination of oxaliplatin and capecitabine (CAPOX) in first and second-line treatment for metastatic colorectal carcinoma (MCRC).

被引：0
|
作者：
Lopez-Vivanco, G [1 ]
Muñoz, A [1 ]
Mañe, JM [1 ]
Ferreiro, J [1 ]
Rubio, I [1 ]
Fuente, N [1 ]
Perez-Hoyos, T [1 ]
Lopez-Argumedo, G [1 ]
Viteri, A [1 ]
Barcelo-Galindez, R [1 ]
机构：
[1] Hosp Cruces, Bilbao, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3701
引用
收藏
页码：294S / 294S
页数：1
相关论文
共 50 条
  • [1] Oxaliplatin and capecitabine (CAPOX) is active and feasible for irinotecan refractory metastatic colorectal carcinoma (MCRC)
    Munoz, Alberto
    Viteri, Ainboa
    Rubio, Itziar
    Alvarez, Aitor
    Mane, Joan M.
    Pardo, Marta
    Fernandez, Ricardo
    Lopez-Argumedo, Gonzalo
    Barcelo, Ramon
    Lopez-Vivanco, Guillermo
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 92 - 92
  • [2] Capecitabine and oxaliplatin (XELOX) as first line treatment for patients with metastatic colorectal cancer (MCRC)
    Karacetin, D.
    Maral, O.
    Yalcyn, B.
    Okten, B.
    Incekara, O.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 73 - 73
  • [3] Efficacy and Safety of Capecitabine and Oxaliplatin Combination as Second-Line Treatment in Advanced Colorectal Cancer
    Heras, Panagiotis
    Kritikos, Konstantinos
    Hatzopoulos, Antonios
    Xourafas, Vasihos
    Kritikos, Nikolaos
    Karagiannis, Stefanos
    Mitsibounas, Dimitrios
    [J]. AMERICAN JOURNAL OF THERAPEUTICS, 2009, 16 (04) : 319 - 322
  • [4] Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer
    Borner, MM
    Dietrich, D
    Stupp, R
    Moran, R
    Honegger, H
    Wernli, M
    Herrmann, R
    Pestalozzi, BC
    Saletti, P
    Hanselmann, S
    Müller, S
    Brauchli, P
    Castiglione-Gertsch, M
    Goldhirsch, A
    Roth, AD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) : 1759 - 1766
  • [5] Capecitabine and oxaliplatin as second-line chemotherapy in patients with advanced colorectal carcinoma
    Gennatas, C
    Mallas, E
    Samanidis, L
    Polydorou, A
    Karamanolis, G
    Voros, D
    Komporozos, V
    [J]. PROCEEDINGS OF THE 9TH BIENNIAL CONGRESS OF THE EUROPEAN COUNCIL OF COLOPROCTOLOGY, ECCP, 2003, : 217 - 221
  • [6] Oxaliplatin and Capecitabine (CAPOX) in Non Selected Patients With Metastatic Colorectal Cancer (MCRC) After First-line Irinotecan Based Regimen
    Fonseca, P. J.
    Solis, P.
    Vieitez, J. M.
    Izquierdo, M.
    Pardo, P.
    Gutierrez, E.
    Perez, Q.
    Alvarez, C.
    Frunza, M.
    Uriol, E.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S422 - S423
  • [7] Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of a safety and efficacy analysis
    Arkenau, HT
    Schmoll, H
    Kubicka, S
    Kretzschmar, A
    Freier, W
    Seufferlein, T
    Graeven, U
    Grothey, A
    Hinke, A
    Porschen, R
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 283 - 283
  • [8] Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus Capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of the safety and efficacy analysis
    Arkenau, H.
    Kubicka, S.
    Greil, R.
    Schmoll, H.
    Seufferlein, T.
    Greaven, U.
    Grothey, A.
    Kretschmar, A.
    Hinke, A.
    Porschen, R.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 168 - 168
  • [9] Cetuximab with oxaliplatin and capecitabine (CAPOX)in patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy.
    Grothe, W
    Arnold, D
    Peinert, S
    Voigt, W
    Loeffler, LM
    Siewczynski, R
    Steps, G
    Boehme, J
    Graeven, U
    Schmoll, HJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 288S - 288S
  • [10] First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine, irinotecan, and oxaliplatin (XELOXIRI): Preliminary results of a pilot study by the GONO group
    Burs, S.
    Masi, G.
    Loupakis, F.
    Antonuzzo, A.
    Tognarini, L.
    Sonaglio, C.
    Chiara, S.
    Pfanner, E.
    Brunetti, I
    Petrini, I
    Baldi, G.
    Barletta, M.
    Allegrini, G.
    Ricci, S.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII27 - VII27
12345